Newer Advances in the Management of Hepatitis C
Keywords:
Newer Advances, Hepatitis C, ManagementAbstract
HCV(hepatitis C virus) is single-stranded enveloped RNA virus. Chronic HCV infection is one of the leading causes of liver-related deaths in many countries.About 130-170 million peopleare estimated to be infected with the hepatitis C virus (HCV). Main aim of antiviral treatment targets eradication of the virus. Until a few years ago,the combination of pegylated interferon and ribavirin (PEG/RBV) was the only treatment strategy available and the rates of viral clearance response did not surpass 50% in certain genotypes (1 and 4) with these treatments. In 2011, the first direct acting antiviral agents (DAA), boceprevir and telaprevir were approved for treatment of genotype 1, in combination with traditional dual therapy which accomplished to increase the rates of sustained viral response (SVR) in both naive patients and in retreated patients. New, more effective DAAs have been incorporated since 2013. Besides increasing the rates of SVR, these have pan-genomic properties, excellent tolerance and ease of administration being oral drugs. This has led to shorter therapies, lesser toxicities and regimens free of PEG/RBV, which has enabled their almost generalised applicability in all patients with minimal invasive investigations required.
Downloads
References
Manns, M.P., Maasoumy, B. Breakthroughs in hepatitis C research: from discovery to cure. Nat Rev Gastroenterol Hepatol 19, 533–550 (2022). https://doi.org/10.1038/s41575-022-00608-8
González-Grande R, Jiménez-Pérez M, González Arjona C, Mostazo Torres J. New approaches in the treatment of hepatitis C. World J Gastroenterol. 2016 Jan 28;22(4):1421-32. doi: 10.3748/wjg.v22.i4.1421. PMID: 26819511; PMCID: PMC4721977.
Puri P, Anand AC,Saraswat VA, Acharya SK, Dhiman RK, Aggarwal R et al. Consensus statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part I: status report of HCV infection in India. J Clin Exp Hepatol. 2014 Jun;4(2):106–16.
Dhiman RK. Future of therapy for hepatitis C in India: a matter of accessibility and affordability? J Clin Exp Hepatol. 2014 Jun;4(2):85–6.
Sood A, Sarin SK, Midha V, Hissar S, Sood N, Bansal P et al.Prevalence of hepatitis C virus in a selected geographical area of northern India: a population based survey. Indian J Gastroenterol. 2012 Sep;31(5):232-6
Alter, H. J. et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N. Engl. J. Med. 321, 1494–1500 (1989).
Stramer, S. L. et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N. Engl. J. Med. 351, 760–768 (2004).
Pawlotsky, J.-M. et al. EASL recommendations on treatment of hepatitis C: final update of the series. J. Hepatol. 73, 1170–1218 (2020).
World Health Organization. Combating Hepatitis B and C to Reach Elimination by 2030. WHO https://apps.who.int/iris/handle/10665/206453 (2016).
National Guidelines for Diagnosis and Management of Viral Hepatitis.https://nvhcp.mohfw.gov.in/
Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH et al. Performance of the aspartate aminotransferase‐to‐platelet ratio index for the staging of hepatitis C‐related fibrosis: an updated meta‐analysis. Hepatology. 2011 Mar;53(3):726- 36.
Kim BK, Kim DY, Park JY, Ahn SH, Chon CY, Kim JK,et al. Validation of FIB‐4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus‐infected patients. Liver International. 2010 Apr;30(4):546-53.
Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003 Aug;38(2):518-26
Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006 Jun;43(6):1317-25.
Papastergiou V, Tsochatzis E, Burroughs AK. Non-invasive assessment of liver fibrosis. Ann Gastroenterol. 2012;25(3):218-31
Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006 Jun;43(6):1317-25
Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology.2005 Feb;128(2):343-50
Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–2416.
Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–1206.
Hézode C, Fontaine H, Dorival C, Zoulim F, Larrey D, Canva V, De Ledinghen V, Poynard T, Samuel D, Bourliere M, et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology. 2014;147:132–142.e4.
Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med. 2013;368:1907–1917.
Wong YJ, Kumar R, Kumar R, Tan J, Liu CH, Hui VK, Tan SS, Kao JH, Wong GH, Thurairajah PH. Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor-experienced patients with hepatitis C: Real-world data from a multicenter Asian registry. J Gastroenterol Hepatol. 2022 Aug;37(8):1642-1644. doi: 10.1111/jgh.15918. Epub 2022 Jun 30. PMID: 35723645; PMCID: PMC9543910.
